Protalix Reaches Deal With Brazil | Chemical & Engineering News
Volume 91 Issue 26 | p. 11 | Concentrates
Issue Date: July 1, 2013

Protalix Reaches Deal With Brazil

Department: Business
Keywords: technology transfer, Gaucher disease, enzyme replacement therapy

Protalix BioTherapeutics will transfer the technology for its enzyme replacement therapy to treat Gaucher’s disease, a rare lysosomal storage disorder, to an arm of Brazil’s Ministry of Health. The agreement calls for Protalix to transfer the skills required to make alfataliglicerase for Brazilian patients to Fundação Oswaldo Cruz (Fiocruz) over the next seven years. While Fiocruz constructs a facility, it will purchase at least $280 million of the enzyme from Protalix. Pfizer, which distributes the drug, will receive more than $12 million per year from Protalix during the agreement.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment